Incruse Ellipta (GlaxoSmithKline LLC)


Welcome to the PulseAid listing for the Incruse Ellipta drug offered from GlaxoSmithKline LLC. This Anticholinergic [EPC],Cholinergic Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: GlaxoSmithKline LLC
NON-PROPRIETARY NAME: umeclidinium
SUBSTANCE NAME: UMECLIDINIUM BROMIDE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Anticholinergic [EPC],Cholinergic Antagonists [MoA]
ROUTE: ORAL
DOSAGE FORM: AEROSOL, POWDER
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2014-04-30
END MARKETING DATE: 0000-00-00


Incruse Ellipta HUMAN PRESCRIPTION DRUG Details:

Item DescriptionIncruse Ellipta from GlaxoSmithKline LLC
LABELER NAME: GlaxoSmithKline LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 62.5(ug/1)
START MARKETING DATE: 2014-04-30
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0173-0873_1b9451c9-5180-475e-add7-87294ad92252
PRODUCT NDC: 0173-0873
APPLICATION NUMBER: NDA205382

Other UMECLIDINIUM BROMIDE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
GlaxoSmithKline LLCIncruse Ellipta